J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 361KB） [Members Only]

J.Jpn. Surg. Soc.. 118(4): 407-413, 2017

Feature topic

ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER

1) Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan
2) Department of Specialized Surgeries, Tokyo Medical and Dental University, Tokyo, Japan

Satoshi Okazaki1), Hiroyuki Uetake2)

Based on the results of clinical trials, intravenous 5-fluorouracil/leucovorin (5FU/LV), oral fluoropyrimidine (UFT/LV, capecitabine, and S-1), or oxaliplatin-containing regimens such as FOLFOX and CapeOx are recommended for adjuvant chemotherapy after curative surgery in colorectal cancer patients. Oxaliplatin-containing regimens were reported to show a survival benefit over the 5FU/LV regimen in patients with stage Ⅱ/Ⅲ colon cancer. However, oxaliplatin-containing regimens should be administered carefully in patients with a high risk of recurrence because oxaliplatin is associated with adverse events such as sensory peripheral neuropathy. Further clinical studies and biomarker studies are expected to reveal the appropriate chemotherapy regimen and the patients who are most likely to benefit from adjuvant chemotherapy.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.